NASDAQ:PTGX Protagonist Therapeutics Q3 2025 Earnings Results & Report $139.39 -5.49 (-3.79%) As of 02:18 PM Eastern This is a fair market value price provided by Massive. Learn more. Protagonist Therapeutics missed analyst expectations on both earnings and revenue in its Q3 2025 results, released November 6, 2025. The company reported EPS of -$0.62 versus the -$0.59 consensus estimate, while revenue of $4.71 million fell short of the $5.41 million estimate by $0.70 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 6, 2025TimeBefore Market OpensConference Call3:00 PM ET Protagonist Therapeutics EPS ResultsActual EPS-$0.62Consensus EPS -$0.59Beat/MissMissed by -$0.03One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersProtagonist Therapeutics Revenue ResultsActual Revenue$4.71 millionExpected Revenue$5.41 millionBeat/MissMissed by -$695.00 thousandYoY Revenue GrowthN/AUpcoming EarningsProtagonist Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 2, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Protagonist Therapeutics Q3 2025 Earnings FAQ Did Protagonist Therapeutics beat earnings estimates for Q3 2025? Protagonist Therapeutics (NASDAQ:PTGX) reported earnings of -$0.62 per share for Q3 2025, missing the consensus estimate of -$0.59. The report was announced on Thursday, November 6, 2025. What was Protagonist Therapeutics' revenue for Q3 2025? Protagonist Therapeutics reported revenue of $4.71 million for Q3 2025, against a consensus estimate of $5.41 million. When is Protagonist Therapeutics' next earnings date? Protagonist Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Protagonist Therapeutics on the company's earnings history page. Protagonist Therapeutics Earnings HeadlinesHead to Head Contrast: Protagonist Therapeutics (NASDAQ:PTGX) & AbCellera Biologics (NASDAQ:ABCL)October 13 at 5:15 AM | americanbankingnews.comUBS initiates coverage of Protagonist Therapeutics with buy ratingOctober 12 at 2:43 PM | msn.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 13 at 1:00 AM | Investors Alley (Ad)Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunologyOctober 12 at 2:43 PM | msn.comUBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price TargetOctober 12 at 9:43 AM | marketscreener.comMProtagonist Therapeutics' (PTGX) Outperform Rating Reaffirmed at Leerink PartnersOctober 12 at 9:06 AM | americanbankingnews.comSee More Protagonist Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Protagonist Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protagonist Therapeutics and other key companies, straight to your email. Email Address About Protagonist TherapeuticsProtagonist Therapeutics (NASDAQ:PTGX) (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company focused on developing peptide-based medicines for chronic immune-mediated and hematologic diseases. The company uses its proprietary technology platform to design peptides intended to selectively interact with disease-relevant biological targets. Protagonist’s pipeline includes icotrokinra, formerly known as JNJ-2113, an investigational oral peptide that selectively targets the interleukin-23 receptor. The program is being developed through a collaboration with Johnson & Johnson for conditions including psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. The company is also developing rusfertide, formerly known as PTG-300, an investigational hepcidin mimetic designed to regulate iron availability and treat polycythemia vera and other myeloproliferative neoplasms. Rusfertide is being advanced through a collaboration with Takeda. Founded in 2006, Protagonist is headquartered in Newark, New Jersey, and conducts research and clinical development activities through collaborations and partnerships serving international markets. The company is led by Dinesh V. Patel, who serves as president and chief executive officer.View Protagonist Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09 Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
